Abbott Turns To Flomax Co-Promotion In Anticipation Of Generic Hytrin
Executive Summary
Abbott will co-promote Boehringer-Ingelheim's Flomax (tamsulosin) in an effort to offset imminent generic competition for Hytrin (terazosin).
You may also be interested in...
Abbott To Market Ditropan XL For Five Years: Deal Parallels Alza Merger
Abbott's co-promotion agreements for Ditropan XL with Alza ensure that Abbott will continue to detail the once-daily overactive bladder treatment for the next five years even if the companies do not complete their proposed merger.
Abbott To Market Ditropan XL For Five Years: Deal Parallels Alza Merger
Abbott's co-promotion agreements for Ditropan XL with Alza ensure that Abbott will continue to detail the once-daily overactive bladder treatment for the next five years even if the companies do not complete their proposed merger.
Abbott Expects Prevacid Growth Of 25% Despite Looming PPI Competition
Abbott is expecting 25% U.S. growth for TAP's Prevacid next year, despite potential competition from two new proton pump inhibitors.